Shannon N. Westin, MD, MPH

Shannon Westin, MD, MPH, weighs in on B7-H4 ADCs in gynecologic cancers, focusing on testing, toxicity in maintenance use, and sequencing amid resistance, target shifts, and expanding options.

Shannon N. Westin, MD, MPH, discusses the promising results of the ENPAC trial that showed the effectiveness of adding enzalutamide to standard of care chemotherapy for patients with recurrent endometriod cancer.

Shannon N. Westin, MD, MPH, FACOG, discusses the endometrial cancer patient population enrolled in the phase 3 DUO-E trial.

Shannon N. Westin, MD, MPH, FACOG, discusses the evolving role of immunotherapy as treatment of patients with endometrial cancer.

Shannon N. Westin, MD, MPH, discusses resistance seen with PARP inhibitors in ovarian cancer and how this resistance can be overcome.